U.S. Food and Drug Administration Updates Prescription Drug

Priority Review Continues with Successful Facility Inspections Completed,no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to...

Related Keywords

Iovance Biotherapeutics , Sara Pellegrino , Frederick Vogt , Jen Saunders , Iovance Biotherapeutics Inc , Nasdaq , Exchange Commission , Globenewswire Inc , Drug Administration , Investor Relations Corporate Communications , Priority Review Continues , Successful Facility Inspections Completed , Major Review , Resource Constraints , Expedite Remaining , Priority Review , Biologics License Application , Prescription Drug User Fee Act , Interim President , Chief Executive Officer , Regenerative Medicine Advanced Therapy , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Vice President , Investor Relations ,